In Vitro Release—In Vivo Microbiological and Toxicological Studies on Ketoconazole Lipid Granules

REFERENCES

• Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone. Eur. J. Pharm. Sci. 2001; 12: 261–269
   PubMed Web of Science ®Google Scholar
• Skiba M., Lahiani M.S., Marchais H., Duclos R., Arnaud P. Stability assessment of ketoconazole in aqueous formulations. Int. J. Pharm. Sci. 2000; 198: 1–6
   PubMed Web of Science ®Google Scholar
• Strandberg T.E., Tilvis R.S., Miettinen T.A. Effects of ketoconazole on cholesterol synthesis and precursor concentrations in the rat liver. Lipids 1987; 22: 1020–1024
   PubMed Web of Science ®Google Scholar
• Rodriguez R.J., Acosta D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997; 117: 123–131
   PubMed Web of Science ®Google Scholar
• Yuen K.H., Peh K.K. Simple high-performance liquid chromatographic method for determination of ketoconazole in human plasma. J. Chromatogr. B 1998; 715: 436–440
   PubMed Web of Science ®Google Scholar
• Reynolds J.E.F. K. PorfıttThe complete drug reference. Martindale, The Extra Pharmacopoeia32nd, . Pharmaceutical Press, London 1999; 367–384
   Google Scholar
• Cordoba-Diaz D., Cordoba-Diaz M., Awad S., Cordoba-Borrego M. Effect of pharmacotechnical design on the in-vitro interaction of ketoconazole tablets with non-systemic antacids. Int. J. Pharm. 2001; 226: 61–68
   PubMedGoogle Scholar
• Jackson K., Young D., Pant S. Drug-excipient interactions and their effect on absorption. Pharm. Sci. Technol. Today 2000; 10: 336–345
   Google Scholar
• Saraiya D., Bolton D. The use of precirol to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev. Ind. Pharm. 1990; 16: 1963–1969
   Web of Science ®Google Scholar
• Hamdani J., Moes A.J., Amighi K. Physical and thermal characterization of Precirol and Compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int. J. Pharm. 2003; 260: 47–57
   PubMed Web of Science ®Google Scholar
• Hite M., Turner S., Federici C. Oral delivery of poorly soluble drugs. Part 2. Formulation strategies for solid dosage forms and novel delivery systems for controlled release. Pharmaceutical Manufactoring and Packing Sorcer. 2003
   Google Scholar
• Barthelemy P., Laforet J.P., Farah N., Joachim J. Compritol 888 ATO: An innovative hot-melt coating agent for prolonged-release drug formulations. Eur. J. Pharm. Biopharm. 1999; 47: 87–89
   PubMed Web of Science ®Google Scholar
• Intini G., Aguirre A., Bobek A. Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. Int. J. Antimicrob. Agents 2003; 22: 594–600
   Web of Science ®Google Scholar
• Fidel P.L., Cutright J.L., Sobel J.D. Efficacy of D0870 treatment of experimental candida vaginitis. Antimicrob. Agents Chemother. 1997; 9: 1455–1459
   Google Scholar
• Karasulu E., Kirilmaz L. J.M. AiacheIn vivo evaluation of hydrodynamically balanced capsule with sustained-release of ketoconazole by means of noncompartmental pharmacokinetic analysis. In Proceedings of the Fifth European Congress of Biopharmaceutics and Pharmacokinetics, . Medecine et hygiene: Geneva, Brussels, 150–153, Eur. J. Drug Metab. Pharmacokinet., Special Issue, 1994
   Google Scholar
• Robinson J.R., Eriksen S.P. Theoretical formulation of sustained release dosage forms. J. Pharm. Sci. 1966; 55: 1254–1263
   PubMed Web of Science ®Google Scholar
• Parrot E.L. The effect of disintegrants and pH on disintegration of vaginal tablets. Indian Drugs 1988; 31: 122–124
   Google Scholar
• Gjellan K., Graffner C. Comparative dissolution studies of rectal formulations using the basket, the paddle and the flow through methods. II. Ibuprofen in suppositories of both hydrophilic and lipophilic types. Int. J. Pharm. 1994; 112: 233–240
   Web of Science ®Google Scholar
• Nobilis M., Pour M., Kunes J., Kopecky J., Kvetina J., Svoboda Z., Sladkova K., Vortel J. High-performance liquid chromatographic determination of ursodeoxycholic acid after solid phase extraction of blood serum and detection-oriented derivatization. J. Pharm. Biomed. Anal. 2001; 24: 937–946
   PubMed Web of Science ®Google Scholar
• Suresh B., Sriram S., Dhanaraj S.A., Elango K., Chinnaswamy K. Anticandidal activity of Santolina chamaecyparissus volatile oil. J. Ethnopharmacol. 1997; 55: 151–159
   PubMed Web of Science ®Google Scholar
• Bonhomme-Faivre L., Forestier F., Auchere D., Soursac M., Orbach-Arbouys S., Farinotti R. Chronic administration of verapamil, ketoconazole and carbamazepine: Impact on immunological parameters. Int. J. Pharm. 2002; 238: 133–137
   PubMedGoogle Scholar
• Ozbek E., Turkoz Y., Sahna E. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int. 2000; 85: 742–746
   PubMed Web of Science ®Google Scholar
• Jollow D.J., Mitchell J.R., Zampaglione Y., Gillete J.R. Bromobenzene induced liver necrosis protective role of glutathione and evidence for bromobenzene oxide as the toxic metabolite. Pharmacology 1974; 11: 151–169
   PubMed Web of Science ®Google Scholar
• Cornaire G., Woodley J., Hermann P. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 2004; 278: 119–131
   PubMed Web of Science ®Google Scholar
• Verma R.K., Garg S. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J. Pharm. Biomed. Anal. 2004; 35: 449–458
   PubMed Web of Science ®Google Scholar
• Meshali M.M., El-Sayed G.M., Aleem El-, El- H.M.A., Said Y. Optimisation of theophylline release from tablets containing Compritol. S.T.P. Pharm. Sci. 1995; 6: 429–434
   Google Scholar
• Mirghani A., Idkaidek N. M., Salem M.S. Formulation and release behavior of diclofenac sodium in Compritol 888. Drug Dev. Ind. Pharm. 2000; 26: 791–795
   PubMed Web of Science ®Google Scholar
• Jannin V., Bérard V., N'Diaye A. Comparative study of the lubricant performance of Compritol 888 ATO either used by blending or by hot melt coating. Int. J. Pharm. 2003; 262: 39–45
   PubMed Web of Science ®Google Scholar
• N'diaye A., Jannin V., Bérard V. Comparative study of lubricant performance of Compritol HD 5 ATO and Compritol 888 ATO: Effect of polyethylene glycole behenate on lubricant capacity. Int. J. Pharm. 2003; 254: 263–269
   PubMed Web of Science ®Google Scholar
• Hoeschele J., Roy A.K., Pecoraro V.L., Carver P.L. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob. Agents and Chemother. 1994; 38: 319–325
   PubMed Web of Science ®Google Scholar
• Ozguney I., Ertan G., Guneri T. Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules. Il Farmaco 2004; 59: 549–555
   PubMedGoogle Scholar
• Robinson J.R., Eriksen S.P. Theoretical approach to sustained-release multiple-dose therapy: Noncumulative attainment of desired blood level. J. Pharm. Sci. 1970; 59: 1796–1800
   PubMed Web of Science ®Google Scholar
• Hardman J.G., Limbird L., Goodman A. Imidazoles. Goodman and Gilman's The Pharmacological Basis of Therapeutics10th. McGraw Hill Publishing, Nevada 2005; 1301–1302; 1645
   Google Scholar
• Ozyazici M., Gokce E.H., Ertan G. Release and diffusional modeling of metronidazole lipid matrices. Eur. J. Pharm. Biopharm. 2006; 63: 331–339
   Google Scholar
• Carlson J.A., Henry J.M., Canafax D.M. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am. J. Hosp. Pharm. 1983; 40: 1334–1336
   PubMedGoogle Scholar
• Connors R.D., Elder E.J. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug Dev. Technol. 2004; 4: 245–249
   Google Scholar
• Price J.C., Gore A.Y., Chowhan Z., Holder R.L. Polyethlene glycol. Handbook of Pharmaceutical Excipients. The Pharmaceutical Press, London 1986; 209–213
   Google Scholar
• Walsh S., Shah A., Mond J. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob. Agents Chemother. 2003; 47: 554–558
   PubMed Web of Science ®Google Scholar
• Borysowski J., Weber-Dabrowska B., Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. EBM 2006; 231: 366–377
   PubMed Web of Science ®Google Scholar
• Liu R., Choi J. Age associated decline in gamma-glutamyl sisteine sentase gene expression in rats. Free Radic. Biol. Med. 2000; 28: 566–574
   PubMed Web of Science ®Google Scholar